FMD Explained: A Guide to Pharma Serialization & Barcodes

Managing labeling and identification in pharmaceutical supply chains is critical for patient safety and regulatory compliance. Amid the rising threat of substandard and falsified medicines, regulatory bodies worldwide have mandated serialization of drug packages (uniquely identifying each unit) and standardized barcodes to enable track-and-trace from manufacture to dispensation (^[1]) (^[2]). The European Union’s Falsified Medicines Directive (FMD) – Directive 2011/62/EU, supplemented by Commission Delegated Regulation (EU) 2016/161, which has applied since 9 February 2019 – requires medicines within scope to bear safety features: a two-dimensional barcode encoding a unique identifier and an anti-tampering device. The identifier includes a product code, serial number, batch number, expiry date and, where applicable, a national reimbursement or identification number; GTIN is a common implementation choice, not a legal requirement (^[3]) (^[4]). By scanning at pharmacies or wholesalers, the European Medicines Verification System (EMVS) checks each serial code against a repository to confirm authenticity (^[5]) (^[6]). Similar systems have been adopted globally. In the United States, the Drug Supply Chain Security Act (DSCSA, 2013) requires a product identifier—NDC, serial number, lot number, and expiration date—on covered prescription-drug packages and homogeneous cases. Statutory product exclusions and exemptions apply.

This report surveys the historical evolution, technical elements, implementation approaches, and impacts of supply-chain labeling and serialization in pharmaceuticals, with special focus on the EU FMD framework. We examine how barcoding standards (e.g. GS1 data-matrix) and serialization work in practice, the costs and benefits experienced by manufacturers and pharmacies, and real-world outcomes such as detection of falsified Avastin (cancer drug) in 2019 via FMD scanning (^[6]). We also profile broader trade impacts, comparing global regulatory approaches, costs of compliance (one Irish study found serializing added ~4.1 €‐cents per pack and multi-million-euro annual spend (^[7])), and pharmacy staff experiences (e.g. 82% of Irish pharmacists felt patient wait-times increased under FMD scanning (^[8])).

Data and case studies are cited to assess effectiveness: since FMD implementation only dozens of falsifications have been officially confirmed in EU/EEA (^[9]), but even a single intercept prevents potentially lethal errors. We discuss ongoing challenges (data management, interoperability, training, error rates) and future directions (expansion to wholesalers, enhanced analytics, blockchain trials (^[10])). The report concludes that while serialization entails significant investment and workflow changes, it provides an unprecedented toolset for supply-chain security, patient safety, and regulatory oversight, with lessons applicable beyond healthcare as a model for product integrity.

Pharmaceutical supply chains are inherently global, complex, and high‐stakes. Drugs pass through multiple tiers – active ingredient manufacturers, formulators, packaging contractors, wholesalers, pharmacies and sometimes across national borders – before reaching patients. This complexity opens opportunities for counterfeit or falsified medicines to enter the legitimate supply chain, posing grave health risks (^[11]) (^[12]). Falsified or counterfeit drugs may contain wrong or toxic ingredients, incorrect dosage, or no active ingredient, and crucially bypass normal regulatory controls (^[13]) (^[12]). The World Health Organization (WHO) estimates that at least 1 in 10 medicines in low- and middle-income countries are substandard or falsified (^[14]); even in developed markets, incidents like the Heparin contamination (2008) and transnational shipment of fake Avastin (2012) underscore vulnerabilities (^[15]) (^[16]).

To safeguard patient health, authorities worldwide have moved towards rigorous track-and-trace requirements. Beginning in the late 2000s, regulators recognized that assigning a unique identity to each saleable unit could prevent the diversion of illegitimate products. This serialization means every pack receives a unique code, often encoded in a 2D barcode, that can support authentication and other supply-chain processes (^[1]). The idea, long used in other industries (automotive, electronics), gained prominence in healthcare with initiatives like the U.S. FDA’s pilot Project24 in 2007, followed by regulations. In the EU, the Falsified Medicines Directive (2011/62/EU) was adopted in 2011, amending the EU’s fundamental pharmaceutical law (Directive 2001/83/EC) to mandate safety features on medicine packs (^[3]) (^[17]). The Directive took effect in 2013 and was fleshed out by Delegated Regulation 2016/161 (effective Feb 2019), which specified the unique identifier format and verification system (^[18]). Simultaneously, other countries launched national schemes (Turkey’s ITS in 2012, Brazil’s SNCM system enacted 2016, UAE, etc.), and the U.S. passed the Drug Supply Chain Security Act (DSCSA) in 2013 to require serial codes on drug packages by 2023 (^[19]) (^[20]).

Serialization vs. Barcoding. Here “serialization” refers to generating and managing unique serial numbers for each pack; “barcodes” refer to the printed symbols encoding those numbers. In practice, worldwide standards (chiefly those of the GS1 organization) define how data is encoded on labels. In Europe, FMD requires a two-dimensional Data Matrix on packs within scope, carrying specified unique-identifier data elements; GS1 DataMatrix and GTIN are common implementation choices, not exclusive legal requirements (^[21]). Retail packaging may still include a traditional EAN/UPC barcode for shelf scanning, but the FMD Data Matrix is used to encode the unique identifier for authenticity verification and decommissioning. The unique serial code may appear once or repeated on carton, leaflet, or brush-over labels on ampoules (^[22]) (^[9]). Crucially, when a pack is supplied to the public, exported, or handled in another circumstance specified by the Regulation, its identifier is verified and may be “decommissioned” in the repositories system so that it cannot be reused. The identifier is verified through the EMVS repositories network, rather than through a regulator-established central database.

This report dissects these processes in depth. We explain the technology (data carriers, GS1 standards, tamper-evident seals), the regulation (EU FMD’s legal framework and others), the implementation (how manufacturers and pharmacies adapt), and the impact (statistical results, case examples, industry surveys). We contrast perspectives of stakeholders – regulators, manufacturers, contract packagers, distributors, pharmacists, patients – and explore lessons from early adopters. By combining data (e.g. a recent Irish study quantifying serialization cost (^[7]) and a pharmacy survey on FMD burden (^[8])) with expert analysis, the report furnishes a granular, evidence-backed view suited to supply chain and regulatory professionals.

EU Falsified Medicines Directive (FMD)

The EU Falsified Medicines Directive (Directive 2011/62/EU) was adopted by the European Parliament and Council in 2011 to combat entry of falsified medicines into the legal supply chain (^[3]) (^[17]). It amended Directive 2001/83/EC (the EU’s Community Code for human medicines) to introduce “safety features” on packaging: a unique identifier and an anti-tampering device for prescription medicines generally, subject to the listed exclusions in Annex I. Member States may also extend the scope to specified non-prescription medicines (^[2]) (^[4]). The Directive became effective January 2013 (^[3]).

Key measures mandated by FMD include (^[2]):

• Unique Identifier: A multi-field identifier encoded in a machine-readable Data Matrix on the packaging. It includes a product code, serial number, batch number, expiry date and, where required, a national number. GS1 DataMatrix and GTIN are common implementations, not universal legal mandates.
• Anti-tampering device: A physical feature (printed breakable seal, blister seal, etc.) ensuring each pack’s integrity after manufacture.
• “.eu” common logo: A mandatory logo on legal online pharmacy websites (to combat internet sales of fake meds). (While not directly on the package, this is an FMD measure.)
• Record-keeping enhancements: Tougher wholesaler documentation requirements, and stricter rules on API (active pharmaceutical ingredient) imports.

Directive 2011/62/EU was a framework: it required the Commission to adopt detailed technical rules. Those came in Commission Delegated Regulation (EU) 2016/161, published Oct 2015, which specified how serialization should be done (^[23]) (^[24]). Delegated Regulation 2016/161 entered into force Feb 9, 2019 (^[23]) (^[18]) after a 3-year transition period. Its recitals and articles set out that medicines within scope must bear a unique identifier and an anti-tampering device; compliance with international standards can demonstrate compliance but is not mandatory (^[25]) (^[26]); the unique identifier must be printed in both machine-readable 2D code and human-readable text (^[27]); and a Europe-wide repository system (EMVS) would be established, into which MAHs (marketing authorization holders) upload all codes (^[28]) (^[29]).

In summary, since 9 February 2019 the FMD framework has required medicines within scope to bear a two-dimensional Data Matrix containing a unique identifier and an anti-tampering device, with national and supranational repositories connected through a central repository that acts as an information and data router. No member-state can implement alternative authentication methods; the rules are harmonized across the EU (^[25]) (^[30]). The required two-dimensional Data Matrix encodes the following unique-identifier elements; GS1 is a common implementation standard (^[21]) (^[27]): the product’s GTIN, a randomized serial number, the batch/lot number, and the expiry date. This “unique identifier” is mathematically unique to each pack, and by law it must remain unique up to at least 5 years after sale (^[31]).

EU FMD legislation explicitly notes the purpose of these data fields: inclusion of product code, batch and expiry “contributes to patient safety by facilitating recall, withdrawal and return procedures and pharmacovigilance” (^[29]) (^[32]). In practice, when a pharmacy dispenses a medicine it scans and “decommissions” the unique identifier via the national Medicines Verification System – effectively marking it as dispensed so it cannot be reused (and checking it against the database of all legitimate packs) (^[5]). If a scan finds a mismatch (e.g. duplicate serial or unknown code), the pack is quarantined. Thus FMD provides an end-to-end verification: every legit pack is verified at dispense, and falsified packs can be intercepted earlier (as in the Avastin case below). After rollout, compliance was staggering: the European Commission’s 2024 evaluation report (COM(2024)274) confirmed only 30 cases of falsified medicines in the legal supply chain between 2011 and 2024, with just 11 confirmed cases since 2019 (^[33]). By February 2026, the EMVS celebrated seven years of continuous operation, connecting over 2,900 Marketing Authorisation Holders, 4,000 wholesale distributors, 115,000 commercial pharmacies, and 6,000 hospital pharmacies across Europe (^[34]).

Key FMD Provisions: Manufacturers and authorised repackers must apply a unique identifier in a two-dimensional barcode and an anti-tampering device to prescription medicines within scope; listed exclusions apply, and specified non-prescription medicines may be included. [Directive 2011/62/EU (OJ L174, 2011)] (^[3]) (^[2]). Delegated Regulation (EU) 2016/161 defines the GS1-compatible data string and verification protocols (^[25]) (^[29]). The repositories system is established and managed by marketing-authorisation holders and manufacturers of medicines bearing the safety features; wholesalers and persons supplying medicines to the public may participate, while national competent authorities are consulted in its establishment and supervise it (^[35]). Medicines within scope are generally verified and their unique identifiers decommissioned when supplied to the public (^[5]).

Across the Atlantic, the US Drug Supply Chain Security Act (Title II of the Food Drug & Cosmetic Act, enacted in 2013) follows the same principle of verifying products, but through transaction records rather than a single EU-style scan system (^[19]). The DSCSA requires manufacturers to affix a Product Identifier to covered prescription-drug packages and homogeneous cases; statutory product exclusions and exemptions apply. The identifier comprises the National Drug Code (NDC – analogous to GTIN) plus a serial number, lot/batch number, and expiration date (^[19]). In 2013, FDA issued guidance aligning this serialized NDC (sNDC) with GS1 standards (^[19]). The DSCSA requires an electronic pedigree: trading partners exchange standardized transaction information for each product movement (^[19]). Unlike the EU, the US system does not use a central repository scan at the pharmacy; instead, every sale is accompanied by a secure electronic record (sometimes via 2D barcode scan on packages, but verified through data exchange). Manufacturers often encode the serialized NDC in a GS1 DataMatrix similar to EU practice, but the approach emphasizes chain-of-custody documentation (^[19]).

FDA issued phased exemptions from specified enhanced drug-distribution-security requirements. FDA currently exempts qualifying small dispensers, and where applicable their trading partners, until November 27, 2027. For this exemption, a small dispenser is one whose owning company has, as of November 27, 2026, 25 or fewer full-time employees licensed as pharmacists or qualified as pharmacy technicians. FDA exemptions under the DSCSA

Many other regions have followed suit. Turkey implemented a nation-wide track-and-trace (ITS) in 2012, requiring aggregation of unit packs to cases, all tracked in a national database (^[36]). Brazil enacted Law No.13,410 in 2016 to create the “National Medicine Control System (SNCM)”, phasing in serialization and reporting rules (implemented by 2023) (^[37]). In the Middle East, Gulf States (e.g. Bahrain) have launched cutting-edge blockchain-based hubs for end-to-end traceability (^[20]). China has rolled out its National Medical Products Administration’s serialized MS codes in phases through 2021–2025. India is piloting serialization (e.g. for vaccines) and is advancing a nationwide Track and Trace System (TTSP). Russia has mandated serialization for all drug classes under its marking system. As of 2026, more than 78 countries worldwide now mandate serialization and traceability compliance for pharmaceutical products (^[38]), and the trend continues to accelerate in emerging markets such as Mexico, Indonesia, and across Africa, where WHO partnerships are promoting harmonization. In all cases, data standards tend to converge on GS1 keys (GTIN or equivalent), though some local encoding schemes exist.

Of note, while nearly all mandates require unique per-unit identification, aggregation requirements vary. In the EU FMD, linking packs to cases (so-called parent‐child aggregation) is not legally required (^[39]) – though companies may adopt it for efficiency – whereas Turkey enforced it and the US DSCSA expects unitization for easier recalls. (The EU law deliberately left aggregation voluntary (^[39]), but many supply-chain partners still implement it in practice to speed scanning of whole pallets.)

Regulatory summary table: Comparison of pharmaceutical labeling regulations across major regions.

Region/Country	Regulation	Effective (Law/Deadline)	Key Requirements
EU (27+EEA)	Directive 2011/62/EU (2011) & Del. Reg 2016/161 (2015) ([3]) ([2])	Directive applies Jan 2013; 2D codes live 9 Feb 2019 ([3]) ([18])	Medicines within scope: a two-dimensional Data Matrix encoding the required unique-identifier elements, plus an anti-tampering device; verification via EMVS/NMVS. GS1 DataMatrix and GTIN are common implementations.
USA	Drug Supply Chain Security Act (2013) ([40])	Phased; qualifying small dispensers, and where applicable their trading partners, have exemptions from specified requirements until 27 November 2027	Covered prescription-drug packages and homogeneous cases require a product identifier (NDC+serial+lot+expiration date); statutory product exclusions and exemptions apply. Electronic transaction records support tracing; there is no unified EU-style verification repository.
Turkey	Turkish ITS (2012)	Implemented 2012 – 2018	Mandatory 2D serialization + aggregation on Rx packs; real-time tracking in NMRA database.
Brazil	ANVISA Law 13.410 (2016)	Implemented 2022–2024	Serialized 2D code per pack; multi-level aggregation; national traceability database (SNCM).
GCC (e.g. Bahrain)	NHRA Blockchain Traceability	2022 onward ([20])	End-to-end serialization & aggregation in blockchain; scanning by all supply-chain parties.

(Sources: EU Commission (^[3]) (^[2]); TraceLink and industry reports (^[19]) (^[20]); country-specific laws. All mandates require per-pack unique IDs, though technical details differ.)

Unique Identifiers and Data Elements

Under modern supply-chain labeling, each medicine package is marked with a unique identifier that encodes the essential data about that pack (^[21]). By regulation, the FMD’s unique ID consists of the following data elements (^[21]) (^[32]):

• Product code: identifies the medicinal product and its packaging configuration. A GTIN is a common GS1 implementation, but the Regulation does not require GTIN specifically.
• Serial Number: a randomized, non-repeating number unique to that single pack (often 14 alphanumeric characters). It must be unpredictable to thwart forgers (^[41]).
• Batch/Lot Number: the manufacturer’s lot code, linking the pack to a production batch for recall and quality purposes.
• Expiration Date: formatted as YYMM or similar, to ensure timely usage/withdrawal.

Delegated Regulation 2016/161 specifies a product code, serial number, batch number, expiry date and, where applicable, a national reimbursement or identification number; it does not prescribe GTIN as the product-code format (^[29]) (^[32]). These four fields are encoded in a single machine-readable code. (Some versions also incorporate a national reimbursement code for countries with national numbering; the goal is always to include ample data for traceability (^[32]).)

The format of the unique-ID data string must use an internationally recognised, standardised data syntax and semantics that allows common scanning equipment to identify and decode each element. GS1 Application Identifiers are a widely used implementation, but the Regulation does not make GS1 the only permitted coding scheme. (^[42])

Crucially, encoding both serial and batch/expiry makes each pack uniquely identifiable and time-limited. If a pack is recalled (because its batch or expiry is compromised), scanning flags it. If it’s illegitimately re-entered (duplicate serial), the database will show it’s already been used (^[32]) (^[6]). EU law requires the product code and serial number, and the national reimbursement or identification number where applicable, to be printed in human-readable form alongside the barcode, subject to the small-pack exception (^[27]).

Barcode Symbologies

The data carriers chosen for these codes are largely barcodes (and increasingly QR/barcode hybrids). In Europe, the Regulation requires a two-dimensional Data Matrix encoding the unique identifier; GS1 DataMatrix is a common implementation, rather than a named universal legal mandate. The GS1 DataMatrix is an ISO/IEC 16022 ECC200 symbol with GS1 FNC1, designed for high-density encoding (^[43]). It can encode variable-length data strings (numeric or alphanumeric) in a compact square of dots (^[44]). The 2D DataMatrix is favored because of its small footprint (suitable for cramped medicine cartons), error correction, and ability to store multiple fields.

Other barcodes appear in packaging and shipping:

• GS1-128 (Code 128) is a linear (1D) barcode commonly used on larger labels. It can carry any GS1 key with AI prefixes, up to about 48 alphanumeric characters per symbol (^[45]). Manufacturers may use GS1-128 on secondary packaging or pallets to encode GTIN and serial in case-level coding. However, EU/FMD specifically requires a 2D code on primary packs.
• ITF-14 (Interleaved 2 of 5) is a 1D barcode that encodes a 14-digit GTIN (without serial/attributes) for use on corrugated master cases (^[46]). It is not used for individual pack serialization, but for bulk logistics. The GS1 specification notes: “ITF-14 barcode can only hold the GTIN and is suitable for printing on corrugated materials” (^[46]).
• QR Codes and Other 2D: Conventional QR Codes are not the FMD-required carrier; the Regulation requires a two-dimensional barcode meeting its unique-identifier requirements. QR Codes can, however, carry GS1 Digital Link data and support consumer-facing or other digital applications. FMD serialization commonly uses GS1 DataMatrix.

A comparison of common barcode symbologies in pharma labeling:

Barcode Type	Dimension	Data Capacity (approx)	Typical Use
GS1 DataMatrix (ECC200)	2D	Variable (hundreds to thousands of characters) ([44])	Item-level unique ID (GTIN+SN+Batch+Exp) on medicine packs (required by FMD) ([21]).
GS1-128 (Code 128)	1D	~48 alphanumeric per symbol ([45])	Case/pallet labeling or secondary packaging: can encode GTIN with attributes (serial/lot/exp) for shipments.
ITF-14	1D	14 numeric digits ([46])	Bulk/logistics: encodes GTIN of a case (no serial, for carton labeling).
QR Code	2D	Varies by symbol version and encoding	Consumer/mobile engagement and optional supply-chain applications; QR Codes can carry GS1 Digital Link data but are not the FMD-required carrier.

(Sources: GS1 specifications (^[46]) (^[45]) (^[43]); delegated reg and industry guides (^[21]).)

In addition to the barcode, pharmaceutical labels include human-readable information: brand name, active ingredient, dosage form, strength, packaging count, manufacture details, etc. Under FMD, the product code and serial number, and the national reimbursement or identification number where applicable, must also be printed in human-readable form on the packaging, subject to the small-pack exception (^[27]), so that if the 2D code cannot be scanned (due to damage or dirt), a pharmacist can still read and manually verify the code (if needed). The EU regulation notes: “The data elements of the unique identifier should be printed on the packaging in human-readable format so as to allow verification … in case the two-dimensional barcode is unreadable” (^[47]).

Tamper-evident features are mandatory. Common implementations include shrink-wrapping a loose leaflet to the box, using a breakable seal over carton tabs, or printing a foil that reveals “VOID” if peeled. These devices signal to the dispenser that the pack has been opened or altered since packaging. Regulation requires that each pack must show a tamper-proof seal or integrated evidence of tamper (^[4]). (Manufacturers often design a scratch-off silver coating or an embossed shrink band around flaps.)

The FMD’s serialization data is managed through a repositories system. Marketing-authorisation holders and manufacturers establish and manage that system, while national competent authorities are consulted during its establishment and supervise it. National and supranational repositories exchange data through a central repository that acts as an information and data router; it is not a regulator-established central database. As of early 2026, the EMVS connects over 2,900 Marketing Authorisation Holders, 4,000+ wholesale distributors, 115,000+ commercial pharmacies, and 6,000+ hospital pharmacies (^[34]). Italy and Greece, which had operated parallel national systems, were required to join the full EU system by 2025 (^[48]). When manufacturers/MAHs package a medicine, they generate serial numbers and upload the unique-identifier data for each pack into the repository system. That data includes a product code, serial number, batch number, expiry date and, where applicable, a national reimbursement or identification number. Thus EMVS contains the “master list” of all legitimate codes in circulation (^[5]) (^[31]). When a pack is dispensed or leaves the supply chain, the pharmacist or authorized person scans the 2D code; the scan queries the EMVS: if the code is valid and not yet decommissioned, the system returns “OK” and marks it as used. If the code was never registered, already marked, or mismatched, an alert is raised.

This end-to-end verification is the heart of FMD. Crucially, decommissioning ensures a serial number cannot be reused by criminals. Regulators noted that “the effectiveness of an end-to-end verification system…depends upon the verification and subsequent decommissioning of the unique identifier of every supplied pack, so that that unique identifier cannot be re-used by traffickers” (^[49]). Data thus flows in real time: every legitimate sale updates the repository. This can support post-market surveillance, such as investigation of suspicious events. When a pack is marked recalled in the repository, verification can prevent its supply to the public; however, the FMD repository is an authenticity-verification and status system, not a complete record of each pack’s physical location or dispensing pharmacy.

Implementing serialization requires major changes at packaging lines and in IT systems. Primary adjustments include installing printers (for barcodes), cameras/vision systems for 100% checking, and line controllers capable of interfacing with Level 4/5 software and the EMVS. Each pack-out must incorporate a scanned or printed code, plus the usual labeling steps. According to industry sources, one of the most critical decisions is whether to adapt existing packaging lines or install new equipment for serialization devices (^[50]). Even hardware aside, software and data integration is equally vital. Patrick L. (ContractPharma) notes that after selecting hardware, companies then invest heavily in serialization software, linking backend databases to line execution so that each GTIN/SN is correctly matched to each package (^[51]).

These investments are substantial. A recent industrial study in Ireland found that manufacturers underestimated costs: “the capital costs of serialization were four times greater than those estimated by the regulators.” Across 114 production lines (65% of Ireland’s automated lines), serialization added on average €0.041 per pack and up to €4.5 million annually for a large site (^[7]), raising the cost of goods sold by ~2.7%. Line efficiency was measurably reduced by serialization-related downtime and error handling (^[7]). This quantitative evidence underlines the heavy resource burden: multi-million euro outlays, new labeling equipment, IT systems, and worker retraining.

The data element management is also complex. Companies must generate millions of unique serials, ensure no collisions, randomize properly, and periodically synchronize with third-party IT systems (CMOs, repackagers). Serialization projects often require multi-year planning. A packaging expert notes, “Often companies are supplying to more than one market, meaning there are multiple different regulations… no one-size-fits-all approach. The key is developing a flexible solution that can be adapted depending on the market.” (^[52]) For example, a product shipped to both EU and non-EU countries may need different label formats or code formats on different cartons (leading to dual-labeled boxes). This regulatory variance greatly increases project scope and cost (^[52]).

Counterfeit Prevalence and Detection

The underlying goal of these measures is to deter falsified products. How prevalent are they, and how effective is serialization in practice? Official data suggest the legal supply chain in Europe has very low levels of falsification. The European Commission's comprehensive 2024 evaluation report (COM(2024)274) confirmed only 30 cases of falsified medicines detected in the legal supply chain between 2011 and 2024, with just 11 confirmed cases since the FMD's verification system went live in 2019 (^[33]). Most falsification cases were detected in the illegal supply chain, often via unauthorised online sales. However, the Commission cautioned that a full assessment was not yet possible because Greece and Italy were only due to join the EU system in 2025, and six Member States still allowed dispensing of packs that raised alerts in the system (^[33]). As the Commission notes, without standardized reporting systems and full system adoption, ”it is difficult to assess how the situation has evolved.” (^[33]). In 2025, the European Medicines Verification Organisation (EMVO) was accepted as an observer to the Council of Europe's MEDICRIME Convention, reflecting the growing international cooperation on pharmaceutical crime (^[34]).

On the positive side, a leading example of the system at work occurred immediately after FMD launch. In June 2019, a Dutch pharmaceutical wholesaler scanning a shipment flagged four boxes of Roche’s Avastin (cancer drug) as suspicious. The boxes, in Bulgarian labeling, turned out to be falsified. The national inspectorate reported this was “one of the first times” the new FMD verification system had protected patients from fake drugs (^[6]). The packs were seized before reaching any pharmacy, demonstrating the potentially life-saving interception enabled by serialization. This case underscores the intended benefit: alerting on suspicious codes prevented “patients from being exposed to the illicit product” (^[6]).

Beyond single cases, serialization creates rich datasets for analysis. Companies and regulators can track volumes of scans, false positives, and audit trails. For example, if a particular serial is scanned multiple times (indicating theft/diversion), the system can raise region-specific alarms. No large-scale public data on interdictions has been released yet, but industry analysts highlight that any intercepted counterfeit (even a handful of packages) is an important win for public confidence. As PharmaFocus Europe notes, “serialization boosts patient safety, transparency, and recall efficiency” (^[10]), which includes simply not dispensing a fake pack.

Economic and Operational Impacts

Serialization’s costs are most acute for manufacturers and packagers. Aside from capital outlay, there are operational impacts: lines may slow for inspection; quality assurance staff must review exceptions; regulatory reporting adds bureaucracy. The Irish study (^[7]) quantified these: a 65% uptake of serial lines, with significant capital costs (4× higher than regulators assumed) and a tangible rise in per-pack cost. Companies also change their production patterns: many shifted from small batch runs to larger batches to amortize the label printing overhead. The study even proposed using a “serialization depreciation factor” when calculating product costs, reflecting that the extra expense diminishes as equipment ages (^[7]).

Distributors and pharmacies face mixed impacts. On one hand, wholesalers must update warehouses and IT to handle serialized scanning. On the other hand, enhanced data allows them inventory visibility. For medicines within FMD scope, persons authorised or entitled to supply medicines to the public generally verify and decommission the unique identifier at supply, subject to the Regulation’s derogations and Member State exemptions. An Irish survey (618 pharmacists) found operational downsides: 82% reported longer patient wait times, and 65% said they spent less time counseling patients because of the required scans (^[8]). Only 28% felt the directive actually improved patient safety (despite its intent) (^[8]). Some pharmacists noted increased error rates: “the number of near misses and error count increased after introduction of scanning,” reflecting new workflows (^[53]). (It seems pharmacies initially had insufficient training or process-optimization for the scanning step (^[54]) (^[53]).) These perceptions highlight the human factor: any new step in dispensing can introduce friction or mistakes if not well integrated.

Industry reports similarly emphasize the human and technical facets. A contract packing executive explained that beyond scanners and printers, “the software requirements are arguably more important… all the data needs to be easily accessed by supply-chain systems” (^[55]). Companies invested in cloud-based Track & Trace platforms linking manufacturers’ databases to line machinery (^[56]). These IT layers (sometimes called “Level 4/5” enterprise systems) were essential for handling orders and serial data flow (^[57]).

On the positive side, many companies foresee long-term ROI. A 2012 Business Leader article notes that next to compliance, serialization will improve recall efficiency and supply-chain assurance (^[58]). Bristol-Myers Squibb, for instance, invested early: it views serialization data as a strategic asset to improve patient safety, social responsibility, and logistics. BMS reported that “with the improved supply chain visibility… we’ll see the pathway a product follows from our distribution center all the way to the customer,” enabling quicker decisions and better reverse logistics (^[59]). Thus far, few companies provide hard ROI figures, but the evidence suggests a gradual shift: serialized data can eventually enable automated inventory management, targeted recalls (vs. whole-batch withdrawals), and anti-diversion analytics (e.g. spotting irregular ordering patterns).

• Malicious diversion prevented (Avastin, EU): As noted, a wholesaler in the Netherlands used FMD scanning to detect four packages of falsified Avastin (^[6]). The system notified the inspectorate, packets were seized, and no patients received them. This real-world interception demonstrates how serialization can integrate with seizure workflows. The incident was widely publicized as evidence FMD works.
• Pharmacist workflow (Ireland survey): Published research showed community pharmacists largely complied with FMD scanning but at the expense of time with patients (^[8]). Post-FMD, 82% of pharmacists said dispensation was slower, 65% that consultation time fell, and surprisingly only 28% believed patient safety was improved, reflecting frustration (^[8]). Qualitative comments noted system glitches caused near-miss errors (^[53]). This suggests that regulators and pharmacies underestimated change management: workflows, training, and system reliability needed more attention.
• Manufacturer implementation (Stegemann packer): A German contract packager, Stegemann, illustrates a typical technical solution (^[60]). The company installed Mettler-Toledo’s T11 printer-inspect system: a vision camera reads every DataMatrix to verify accuracy, rejecting any misprinted labels (^[60]). Orders flow through a cloud (TraceKey) platform: MAHs upload serials, Stegemann creates label orders, and the XML data flows into the on-line PLM software that drives the fill-line (^[56]). This setup – printers + inline camera + cloud middleware – is now common in pharma contract packaging. It ensures 100% verification at print time, preventing faulty labels from leaving the factory.
• Operational efficiency (Irish study): The O’Mahony study (^[7]) is instructive. By instrumenting production lines and costs, it quantified serialization overhead: a high-volume site saw up to €4.5M/year incremental cost, and 2.7% rise in unit COGS. Many firms were not fully prepared (regulators’ cost estimates were far too low). The study’s conclusions are sobering: serialization does reduce operational efficiency in the short term (lower OEE, line speed losses) and must be planned as a significant capital spend. It is a cautionary tale for firms in other regions viewing serialization as a low-margin exercise.

These case inputs – both successes and pains – help gauge the real impact of serialization mandates. Broadly, benefits seen include thwarting known counterfeits, tightening recalls, and eventually improved supply-chain visibility. Costs include infrastructure investment and time delays, especially for small producers. Stakeholder surveys indicate skepticism about immediate patient-impact improvements, although the ultimate goal remains long-term safety.

Wider Implications for Public Health and Commerce

Serialization and standardized labeling reshape pharmaceutical commerce. For patients and regulators, the principal safety benefit is authenticity verification: for products within scope, the system can check an identifier against repository data and decommission it when required. It does not establish a complete physical lineage for every dispensed pack. As EMA notes, falsified medicines “are a serious threat to global health” (^[61]), and serialization directly targets that risk. By making it extremely costly for criminals to introduce fakes into the legal distribution, the industry can preserve trust in medicines (^[62]) (^[12]). The Avastin example is a minor, but poignant, case where the system functioned as intended.

For manufacturers, serialization is now a regulatory checkbox. But the data can also become value. In an ideal future state, companies will analyze serialization data for supply chain optimization: real-time inventory location, demand forecasting, and identification of low-turnover products. Digital transformation experts suggest serialization will eventually tie into blockchain or IoT frameworks, enabling even stronger end-to-end traceability (^[10]). Some projects (outside pharma) are already exploring on-chain medication logs to assure origin to patients.

Commercial effects vary by jurisdiction and implementation. Common data standards can improve interoperability, but they do not by themselves create global traceability or cross-border data sharing; legal, technical, privacy, and commercial constraints remain.

Supply chain labeling also has knock-on effects. Clear item-level data helps pharmacies manage recalls or shortages at unit granularity. Health systems can record which exact pack a patient received (useful for pharmacovigilance or in case of adverse events). It can deter diversion: if only legitimate pharmacies are authorized to access the EMVS, stolen products flagged as already-dispensed will struggle to enter other markets.

Moreover, as the FMD also required an “.eu logo” on internet pharmacies, the directive integrated around-the-globe online sales as well. Verified pharmacy websites boost consumer confidence, complementing the physical labeling measures.

Challenges and Criticisms

No system is flawless. Critics of serialization note several issues:

• Cost and Burden: Smaller generic manufacturers argue that serializing hundreds of millions of packs is a huge fixed cost relative to tight margins, especially for low-priced drugs. The Irish study’s 2.7% COGS increase (^[7]) shows even medium-sized companies feel the pinch. Similar concerns arose under DSCSA in the U.S.; FDA has issued phased exemptions, including an exemption for small dispensers from specified requirements until November 27, 2027 (^[63]).
• Complexity and Interoperability: Global companies note “varying regulations across markets” making a one-size-fits solution impossible (^[52]). Even within Europe, non-trivial national differences (e.g. parallel trading rules) still exist. Ensuring data quality and system uptime across dozens of stakeholders remains hard. Many repatriated products (parallel exports) require special handling when scanned in different country systems.
• Pharmacy Workflow: As seen in surveys (^[8]), point-of-dispensation scanning adds time. Some pharmacists complained that the scanning step introduced a new error mode (incorrect pack scanned for a different prescription) (^[53]). These human factors mean that warehouse/pharmacy software needs to better integrate scanning prompts and error-checking (some suggestions included audible cues or auto-match to prescription records (^[64])).
• Effect on Patient Safety: Interestingly, many pharmacists did not feel an immediate gain in safety – only 28% in one survey did. One reason may be that most falsified products tend to circulate outside the legal channels, so verifying legal packs “may feel like solving a problem we rarely had.” Critics say resources might be better spent on regulating illicit online sales or supporting enforcement in developing countries, though supporters counter that closing vulnerabilities everywhere is needed.
• Limited Use in Out-of-Chain Falsification: Serialization protects the legal supply chain. But illicit sellers (e.g. illegal online pharmacies not connected to national systems) are not stopped by scanning legal packs, since fake packs often bypass regulation entirely (e.g. coming from non-cooperating nations). Thus some argue serialization doesn’t solve the most prevalent problem globally (fake drugs in informal markets). However, Europe’s system does detect EU-manufactured (or published-for-EU) packs being illegally diverted, which is an improvement.

Overall, the criticisms center on immediate implementation costs and hassle, versus diffuse long-term benefits. Survey and case data suggest the system “works” at its intended purpose, but transitional pains exist for all parties. Nonetheless, international experience shows broad political support; regrets are minor compared to the initial push.

Future Directions and Innovations

Serialization is evolving. Key future avenues include:

• Aggregation and Packaging Hierarchies: While not legally required in EU, many companies are adopting full hierarchical serialization (cases linked to pallets) to speed operations. Automated cameras in warehouses can scan an entire case of unit codes at once (^[65]). Aggregation may improve operational efficiency, but it is not generally required by the EU FMD and its uptake varies by market and supply-chain design. China and others already use multi-level track/trace. Intersection of different strategies may push global standards on carton/pallet coding.

• Blockchain and Distributed Ledgers: Some regions are experimenting with blockchain to record serialized events (e.g. Bahrain’s hub (^[20])). Proponents claim immutable chain-of-custody records could further prevent tampering of data. Pilot projects (notably in supply chains outside pharma) show promise, but pharma faces data privacy and standardization hurdles.

• GS1 Digital Link and Sunrise 2027: GS1’s retail goal is for point-of-sale systems to be able to read and process qualifying 1D and 2D barcodes by the end of 2027. Linear barcodes will remain available and may coexist with 2D codes; Sunrise 2027 does not require their phase-out. While pharma serialization primarily uses GS1 DataMatrix rather than QR codes, GS1 Digital Link can support consumer-facing and digital-information applications.

• RFID/NFC and Beyond-Barcode Technologies: RFID and NFC applications in pharma are projected to grow at a 12.84% CAGR, outpacing traditional barcode incumbents (^[66]). These technologies enable non-line-of-sight scanning, temperature monitoring, and enhanced cold-chain traceability, complementing existing 2D barcode serialization.

• Consumer/Patient Engagement: Future models might let patients scan their medication barcodes with phones to verify they bought legitimate products from authorized pharmacies. In some countries, national apps (“mobile supply chain guard”) are under discussion. This would extend the verification step to the ultimate end-user as an extra check.

• Advanced Analytics and AI: Where lawful and appropriately governed, serialization data may support anomaly detection, investigation of suspicious events, and operational analysis. The usefulness of these applications depends on data quality, access controls, and the limits of the underlying verification system.

• Regulatory Extensions and Divergence: Legislators continue to refine scope. In the EU, extending unique-ID requirements to OTC or parallel-imported products is under consideration, and integration of serialization with anti-diversion efforts (e.g. requiring wholesalers to scan incoming goods rather than just at dispense) is under consultation. Notably, Northern Ireland was disconnected from the EU FMD system effective January 1, 2025 under the Windsor Framework, meaning pharmacies, hospitals, and wholesalers there no longer scan packs against the EMVS (^[67]). Meanwhile, Italy and Greece — long operating parallel national systems — were required to fully integrate with the EU FMD system by 2025, bringing the EMVS closer to comprehensive pan-European coverage.

• Global Coordination: International coordination can improve information sharing on substandard and falsified medicines, but harmonized verification infrastructure and mutual recognition remain future possibilities rather than established global arrangements.

• Beyond Pharma: The serialization model inspires ideas in other fields. The EU's Digital Product Passport initiative (part of the Ecodesign for Sustainable Products Regulation) for electronics, batteries, textiles, and other goods echoes the serial concept for sustainability and trade. Barcodes and IoT tags proliferate on many goods, reflecting the cross-industry applicability of serialization for authenticity and traceability.

In sum, supply-chain labeling supports authentication and verification obligations while creating operational data that may have additional uses. The maturity and scope of serialization infrastructure vary by jurisdiction, product, and supply-chain role.

The move to serialized, barcode-driven supply-chain labeling represents a major transformation in pharmaceutical logistics. Initiated to counter counterfeits, the FMD and similar laws have forced entire industries to upgrade infrastructure, standardize data formats, and rethink processes. While the transition imposes real costs and operational adjustments – documented by manufacturers’ capital spending and pharmacists’ workflow surveys (^[7]) (^[8]) – it yields substantial public health benefits. The evidence from Europe is that the threat of falsified medicines in legal channels has become extremely low. Medicines within the FMD’s scope carry safety features that support verification and more targeted recalls; the framework does not cover every legitimate medicine or every prescription pack without exception.

Multiple perspectives underline that serialization is worthwhile. Regulators achieve their mandate to protect patients from fake drugs (^[4]) (^[68]). Manufacturers gain data that can support authentication and other supply-chain processes, albeit at a cost (^[7]). For medicines within scope, pharmacists can verify the safety features against the repository and decommission the identifier when supplying the pack to the public, although many report that scanning is time-consuming (^[8]). Patients get stronger confidence in medication quality, provided systems are adopted globally. And society benefits from the secondary uses of this data to optimize supply chains and prevent fraud beyond just health care.

The case studies here illustrate concrete results: saving a patient from fake Avastin (^[6]), improving recall processes (^[29]), and spurring corporate initiatives for supply-chain optimization (^[59]). The substantial costs reported (e.g. ~€0.04 extra per pack (^[7])) are a critical fact that stakeholders cannot ignore; any future policy must consider proportionality and support for smaller players. Continuing research and real-world monitoring will refine processes (for example, addressing pharmacies’ concerns (^[8])).

Looking forward, serialization and barcoding are established components of pharmaceutical supply-chain infrastructure. The FMD safety-feature framework supports end-to-end authenticity verification for medicines within scope; its coverage and operational arrangements remain subject to the Regulation, national implementation and applicable exemptions. As serialization requirements evolve across jurisdictions, organizations must continue to monitor the rules that apply to their products and trading partners. The system continues to evolve: automated case scanning, GS1 Sunrise 2027's barcode modernization, RFID/NFC innovations, global data exchanges, and consumer-level verification apps are all advancing. As technology advances (IoT, blockchain, AI), the underlying serialized ID paradigm will enable new services and protections. Ultimately, managing supply-chain labeling is about managing trust: trust that a medicine is what it claims to be. Robust serialization and verification build that trust into every package of medicine.

Tables and Figures: The above includes tables comparing regulations and barcode symbologies, which illustrate key technical and regulatory distinctions. This report draws on EU and FDA documents, peer-reviewed studies, and industry analyses; support should be assessed claim by claim (^[3]) (^[4]) (^[6]) (^[7]) (^[8]) (^[39]). We have prioritized thoroughness and accuracy, grounding all claims in official sources.